Factors associated with high-cost hospitalizations in elderly ovarian cancer patients

被引:4
|
作者
Manrriquez, Erica [1 ]
Mandelbaum, Ava [2 ]
Aguayo, Esteban [2 ]
Zakhour, Mae [1 ]
Karlan, Beth [1 ]
Benharash, Peyman [2 ]
Cohen, Joshua G. [1 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiac Surg, Cardiovasc Outcomes Res Labs CORELAB, Los Angeles, CA 90095 USA
关键词
National Inpatient Sample; High-cost hospitalizations; Operative admissions; Elderly ovarian cancer patients; Open surgery; LAPAROSCOPIC HYSTERECTOMY; CARE; INCOME; USERS; WOMEN;
D O I
10.1016/j.ygyno.2020.09.026
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To characterize factors associated with high-cost inpatient admissions for ovarian cancer. Methods. Operative hospitalizations for ovarian cancer patients >= 65 years of age were identified using the 2010-2017 National Inpatient Sample. Admissions with high-cost were defined as those incurring >= 90th percentile of hospitalization costs each year, while the remainder were considered low-cost. Multivariable logistic regression models were developed to assess independent predictors of being in the high-cost cohort. Results. During the study period, an estimated 58,454 patients met inclusion criteria. 5827 patient admissions (9.98%) were classified as high-cost. Median hospitalization cost for this high-cost group was $55,447 (interquartile range (IQR) $46,744-$74,015) compared to $16,464 (IQR $11,845-$23,286, p < 0.001) for the low-cost group. Patients with high-cost admissions were more likely to have received open (adjusted odds ratio (AOR) 2.23, 1.31-3.79) or extended (AOR 5.64, 4.79-6.66) procedures and be admitted non-electively (AOR 3.32, 2.74-4.02). Being in the top income quartile (AOR 1.77, 1.39-2.27) was also associated with high-cost. Age and hospital factors, including bed size and volume of gynecologic oncology surgery, did not affect cost group. Conclusion. High-cost ovarian cancer admissions were three times more expensive than low-cost admissions. Fewer open and extended procedures with subsequently shorter lengths of stay may have contributed to decreasing inpatient costs over the study period. In this cohort of patients largely covered by Medicare, clinical factors outweigh socioeconomic factors as cost drivers. Understanding the relationship of disease-specific and social factors to cost will be important in informing future value-based quality improvement efforts in gynecologic cancer care. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:767 / 772
页数:6
相关论文
共 50 条
  • [41] Management of high-cost drug requests for exceptional patients
    Bassan, S. S.
    PHARMACY WORLD & SCIENCE, 2008, 30 (06): : 1036 - 1037
  • [42] Improving the management of care for high-cost medicaid patients
    Billings, John
    Mijanovich, Tod
    HEALTH AFFAIRS, 2007, 26 (06) : 1643 - 1655
  • [43] Subgroups of High-Cost Patients and Their Preventable Inpatient Cost in Rural China
    Lu, Shan
    Zhang, Yan
    Ye, Ting
    Kringos, Dionne S.
    INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2024, 13
  • [44] Survival analysis in patients with metastatic colorectal cancer: Correlation with high-cost drug consumption
    Camara, J. C.
    Rosero, A. C.
    Hurtado, A.
    Aguayo, C. I.
    Perez, E.
    Ruiz-Gimenez, L.
    Jara, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S363 - S363
  • [45] Extreme regression models for characterizing high-cost patients
    Gregori, Dario
    Petrinco, Michele
    Barbati, Giulia
    Bo, Simona
    Desideri, Alessandro
    Zanetti, Roberto
    Merletti, Franco
    Pagano, Eva
    JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2009, 15 (01) : 164 - 171
  • [46] Drug expenditure of high-cost patients and their characteristics in Finland
    Saastamoinen, Leena K.
    Verho, Jouko
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2013, 14 (03): : 495 - 502
  • [47] High-Cost Generic Drugs - Implications for Patients and Policymakers
    Uhl, Kathleen
    Peters, John R.
    Flanagan, Keith
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (07): : 685 - 686
  • [48] High-Cost Generic Drugs - Implications for Patients and Policymakers
    Alpern, Jonathan D.
    Stauffer, William M.
    Kesselheim, Aaron S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20): : 1859 - 1862
  • [49] Drug expenditure of high-cost patients and their characteristics in Finland
    Leena K. Saastamoinen
    Jouko Verho
    The European Journal of Health Economics, 2013, 14 : 495 - 502
  • [50] New semiparametric method for predicting high-cost patients
    Maidman, Adam
    Wang, Lan
    BIOMETRICS, 2018, 74 (03) : 1104 - 1111